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Abstract: Iron deficiency and iron-deficiency anemia are associated with increased morbidity and mortal-
ity in a wide range of conditions. In many patient populations, this can be treated effectively with oral
iron supplementation; but in patients who are unable to take or who do not respond to oral iron therapy,
intravenous iron administration is recommended. Furthermore, in certain conditions, such as end-stage
kidney disease, chronic heart failure, and inflammatory bowel disease, intravenous iron administration
has become first-line treatment. One of the first available intravenous iron preparations is iron sucrose
(Venofer®), a nanomedicine that has been used clinically since 1949. Treatment with iron sucrose is par-
ticularly beneficial owing to its ability to rapidly increase hemoglobin, ferritin, and transferrin saturation
levels, with an acceptable safety profile. Recently, important new data relating to the use of iron sucrose,
including the findings from the landmark PIVOTAL trial in patients with end-stage kidney disease, have
been reported. Several years ago, a number of iron sucrose similars became available, although there have
been concerns about the clinical appropriateness of substituting the original iron sucrose with an iron
sucrose similar because of differences in efficacy and safety. This is a result of the complex and unique
physicochemical properties of nanomedicines such as iron sucrose, which make copying the molecule diffi-
cult and problematic. In this review, we summarize the evidence accumulated during 70 years of clinical
experience with iron sucrose in terms of efficacy, safety, and cost-effectiveness.
DOI: https://doi.org/10.1007/s12325-020-01323-z






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Macdougall, Iain C; Comin-Colet, Josep; Breymann, Christian; Spahn, Donat R; Koutroubakis, Ioannis




Iron Sucrose: A Wealth of Experience in Treating Iron
Deficiency
Iain C. Macdougall . Josep Comin-Colet . Christian Breymann .
Donat R. Spahn . Ioannis E. Koutroubakis
Received: February 18, 2020 / Published online: April 15, 2020
 The Author(s) 2020
ABSTRACT
Iron deficiency and iron-deficiency anemia are
associated with increased morbidity and mor-
tality in a wide range of conditions. In many
patient populations, this can be treated effec-
tively with oral iron supplementation; but in
patients who are unable to take or who do not
respond to oral iron therapy, intravenous iron
administration is recommended. Furthermore,
in certain conditions, such as end-stage kidney
disease, chronic heart failure, and inflammatory
bowel disease, intravenous iron administration
has become first-line treatment. One of the first
available intravenous iron preparations is iron
sucrose (Venofer), a nanomedicine that has
been used clinically since 1949. Treatment with
iron sucrose is particularly beneficial owing to
its ability to rapidly increase hemoglobin, fer-
ritin, and transferrin saturation levels, with an
acceptable safety profile. Recently, important
new data relating to the use of iron sucrose,
including the findings from the landmark
PIVOTAL trial in patients with end-stage kidney
disease, have been reported. Several years ago, a
number of iron sucrose similars became avail-
able, although there have been concerns about
the clinical appropriateness of substituting the
original iron sucrose with an iron sucrose simi-
lar because of differences in efficacy and safety.
This is a result of the complex and unique
physicochemical properties of nanomedicines
such as iron sucrose, which make copying the
molecule difficult and problematic. In this
review, we summarize the evidence accumu-
lated during 70 years of clinical experience with
iron sucrose in terms of efficacy, safety, and
cost-effectiveness.
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Key Summary Points
Intravenously administered (IV) iron is
important for individuals who are unable
to tolerate oral iron therapy, who are non-
compliant with oral treatment, or in
whom oral preparations are not effective.
One of the first IV iron preparations to be
manufactured is iron sucrose (Venofer;
Vifor Pharma), which became available for
clinical use over 70 years ago in 1949. It is
the most commonly used IV iron therapy
worldwide, with clinical experience
encompassing 25 million patient-years.
Many studies across a broad range of
therapy areas consistently demonstrate
that iron sucrose is able to correct iron
deficiency, in addition to promoting
erythropoiesis and subsequently reducing
the required doses of erythropoiesis-
stimulating agents (ESAs). Not only is iron
sucrose effective, but it is also well
tolerated and rapidly increases
bioavailable iron supplies.
Since the last review focused on iron
sucrose was published in 2014, reassuring
clinical data have continued to become
available on iron sucrose from a number
of studies. Most notably, the recently
published PIVOTAL trial in patients with
end-stage kidney disease compared the
efficacy and safety of high- versus low-
dose iron sucrose.
Generic substitution of iron sucrose
similar for iron sucrose should not be
assumed to provide therapeutic
equivalence, as the complex
physicochemical properties of the original
agent are extremely difficult to duplicate
and studies have not been able to
conclusively demonstrate that iron
sucrose similars have safety and efficacy
equivalent to that of iron sucrose.
INTRODUCTION
Iron plays an important role in key cellular
metabolic pathways in addition to its role in
heme synthesis and subsequent oxygen trans-
port [1]. Iron deficiency and iron-deficiency
anemia typically occur as a consequence of a
severe underlying condition, such as inflam-
matory bowel disease (IBD), gastrointestinal
(GI) bleeding, chronic heart failure (CHF),
chronic kidney disease (CKD), or cancer [2–9].
Heavy menstrual bleeding and pregnancy may
also result in iron deficiency [10, 11]. Effective
treatment of iron deficiency/iron-deficiency
anemia is important to relieve symptoms,
including extreme fatigue and tiredness, as well
as to alleviate the adverse impact on quality of
life [11–16]. Furthermore, anemia is a risk
amplifier for mortality and morbidity in
patients with heart disease [17] and those with
CKD [18–20]. Iron deficiency, even in the
absence of anemia, can be debilitating and can
exacerbate any underlying chronic disease,
leading to increased morbidity and mortality
[21, 22]; for example, iron deficiency can be
predictive of negative disease outcomes and has
been associated with a worse prognosis in CHF
[23, 24]. Additionally, in patients with iron
deficiency undergoing cardiac surgery, mortal-
ity is elevated threefold, irrespective of the
presence or absence of anemia [25]. Preopera-
tive anemia, which is most commonly caused
by iron deficiency, is also associated with an
increased risk of poor outcomes after surgery
[26, 27]. Iron deficiency and iron-deficiency
anemia generate considerable financial burdens
due to additional medical costs and loss of
productivity [28].
Iron administration is recommended for the
management of iron deficiency/iron-deficiency
anemia associated with a variety of conditions
[2–4, 7–10, 29, 30]. The Network for Advance-
ment of Transfusion Alternatives recommends
that iron deficiency is treated before using ery-
thropoiesis-stimulating agents (ESAs) in
patients with anemia [31, 32]. This is also
advocated in guidelines for the treatment of
anemia in CKD [33, 34]. Corrective strategies to
normalize iron levels and hemoglobin (Hb) are
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recommended as part of perioperative care to
optimize outcomes in patients undergoing sur-
gery [35]. In patients lacking a response to, or
unable to tolerate, oral iron therapy, treatment
with intravenously administered (IV) iron
should be considered [9]. There are also cir-
cumstances in which IV iron is recommended
for use as first-line treatment, including cases of
severe iron-deficiency anemia [2–4] and when
rapid correction of Hb levels is warranted (e.g.,
when less than 6 weeks prior to surgery [35]), or
in certain patient groups with iron deficiency/
iron-deficiency anemia such as those with CHF
[3, 4, 30], hemodialysis-dependent CKD
[3, 4, 8], severe IBD, or cancer [7, 29]. Advan-
tages of parenteral iron therapy include (1)
similar or superior effectiveness, often with a
more rapid response [36, 37]; (2) avoidance of
poor or unreliable intestinal absorption, which
is particularly problematic in patients with
increased hepcidin levels associated with
inflammatory conditions [37]; and (3) improved
tolerability, as the GI side effects of oral iron
therapy are avoided [38]. Several IV iron carbo-
hydrate preparations are available (Table 1).
One of the first IV iron preparations to be
manufactured is iron sucrose (Venofer; Vifor
Pharma), which became available for clinical
use over 70 years ago, in 1949. Indeed, like
aspirin, it is one of the oldest therapeutic agents
still being used widely today. The active ingre-
dient of Venofer is an iron(III) hydroxide–su-
crose complex, and the product is now
registered in 91 countries worldwide. Indeed, it
is the most commonly used IV iron formulation
worldwide, with clinical experience encom-
passing 25 million patient-years [39].
The aim of this article is to provide a com-
prehensive overview of Venofer, focusing
mainly on the characteristics, pharmacokinet-
ics, efficacy, safety, and limitations associated
with this iron preparation. While IV Venofer
has a long history, there are a number of reasons
why a review of its therapeutic use is timely.
Firstly, important new data on the use of this
iron sucrose preparation have recently become
available. A large open-label, blinded-endpoint
study in 2141 patients undergoing hemodialysis
(PIVOTAL study) has recently demonstrated the
clinical benefits of a proactive high-dose iron
regimen of iron sucrose (Venofer) compared
with a reactive low-dose iron regimen, includ-
ing a lower incidence of death, heart attack,
stroke, and hospitalization for heart failure, as
well as reduced ESA dose requirements and use
of blood transfusions [40]. Secondly, various
iron sucrose similars have been developed and
introduced as generic alternatives to Venofer.
However, several recent studies have suggested
that the therapeutic equivalence of Venofer and
follow-on products cannot be assumed, given
that these are complex nanomedicine entities
that may have clinically relevant differences in
their physicochemical properties.
In order to identify peer review publications
of interest, we searched PubMed using the terms
‘‘iron sucrose’’ and filtered results by publication
date (limited to the last 25 years), article type
(clinical trials and reviews), human species, and
English language. This review article is based on
previously conducted studies and does not
contain unpublished data from any studies with
human participants or animals performed by
any of the authors.
PHARMACOKINETICS
AND PHARMACODYNAMICS
Venofer is rapidly cleared from the serum of
healthy subjects, with a terminal half-life of
5.3 ± 1.6 h and total body clearance of
1.23 ± 0.22 L/h (20.5 ± 3.7 mL/min) [41]. Fol-
lowing IV administration of iron sucrose into
patients with anemia, iron is rapidly taken up
by the liver, spleen, and bone marrow [42]. The
majority (97%) of injected iron is utilized for red
blood cell (RBC) synthesis in these patients, and
serum ferritin and transferrin saturation (TSAT)
increase within 24 h and 1 week, respectively
[42]. Furthermore, less than 5% of the overall
elimination of Venofer in healthy individuals
can be attributed to undesirable renal elimina-
tion, due to a relatively large molecular mass
(greater than 18 kDa) [21].
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Table 1 Overview of characteristics of approved IV iron formulations. Adapted from Muñoz and Martı́n-Montañez. Reprinted by permission of the publisher
(Taylor & Francis Ltd, https://www.tandfonline.com) [175]






Brand name Ferrlecit Venofer Cosmofer Ferinject,
Injectafer
Monofer FeraHeme




















Molecular weight measured by
manufacturer, kDa
289–440 34–60 165 150 150 750
Initial distribution volume, L 6 3.4 3.5 3.5 3.4 3.16
Terminal half-life (dose in mg Fe)
[176]







Labile iron, % of dose 3.3 3.4 1.9 0.6 1 0.9
Direct iron donation to
transferrin, % of dose
5–6 4–5 1–2 1–2 \ 1 \ 1
Iron content, mg/mL 12.5 20 50 50 100 30
Maximal single dose, mg
(minimum administration
time)a [176, 177]




1000 (15 min) 20 mg/kg BW
(1 h)
510 (15 min)
BW body weight, IV intravenously administered, LMWID low molecular weight iron dextran




























Efficacy of Iron Sucrose in Various
Conditions
The efficacy of iron sucrose has been demon-
strated in a wide range of conditions that cause
or are associated with iron deficiency and iron-
deficiency anemia, as summarized below. Across
these various conditions, iron sucrose treatment
is associated with improved iron status (ferritin,
TSAT); increased Hb levels, with or without ESA
therapy; and improved health-related quality of
life and clinical outcomes. When used in com-
bination with ESA therapy, iron sucrose sub-
stantially reduces ESA dose requirements.
Chronic Kidney Disease
As summarized in Table 2, studies have consis-
tently reported that iron sucrose is an effective
treatment for iron deficiency/iron-deficiency
anemia in patients with CKD, leading to
increased Hb, serum ferritin, and TSAT in
patients regardless of whether they are under-
going hemodialysis or receiving ESAs
[40, 43–54].
In adults undergoing maintenance
hemodialysis, differing regimens, including
continuous and intermittent administration of
iron sucrose, have been examined
[40, 43, 46–48, 50, 55]. While each of these
studies has demonstrated benefits of iron
sucrose in maintenance hemodialysis, the most
conclusive results are reported in the recent
PIVOTAL study, a landmark trial that is already
changing clinical practice and will almost cer-
tainly impact on future clinical guidelines.
PIVOTAL was a multicenter, open-label trial
with blinded-endpoint evaluation in 2141
hemodialysis patients; it is the largest prospec-
tive, controlled clinical trial of IV iron in
patients with CKD [40]. In the PIVOTAL trial,
patients were randomized into two groups: one
receiving high-dose iron sucrose proactively
(400 mg monthly; with temporary discontinu-
ation of treatment if safety cutoffs of ferritin
700 lg/L or TSAT of 40% were exceeded) and
the other group receiving low-dose iron sucrose
administered reactively (0–400 mg monthly,
adjusted to achieve minimum targets for ferritin
and TSAT of 200 lg/L and 20%, respectively)
[40]. Importantly, within the context of a rig-
orous study design, this study showed that the
risk of cardiovascular adverse events (AEs),
infections, hospitalization, and death was lower
or similar with high-dose iron sucrose compared
with low-dose iron sucrose.
High-dose iron sucrose was superior to low-
dose iron sucrose with respect to the primary
composite endpoint of non-fatal myocardial
infarction, non-fatal stroke, hospitalization for
heart failure, or death (p\0.001 for non-infe-
riority; p = 0.04 for superiority) [40]. The effect
of high-dose iron sucrose on the primary end-
point was consistent across all of the prespeci-
fied subgroups (duration of dialysis treatment,
diabetes status, and vascular access). In addi-
tion, proactive administration of high-dose iron
appeared to protect against recurrent cardio-
vascular events. An additional benefit of high-
dose iron sucrose was the subsequent reduction
in ESA dose required by patients in this group
and the reduced likelihood of requiring blood
transfusions [40].
Relative to the low-dose strategy, the high-
dose approach to iron sucrose administration
was not associated with any safety signals.
There was no difference in vascular access
thrombosis, or in hospitalizations between the
dosing groups [40]. Additionally, infection rates
were virtually identical between the high-dose
and low-dose iron sucrose groups, suggesting no
association between iron dose, ferritin/TSAT,
and the risk of infection [40, 56]. This is reas-
suring because it has been previously suggested
that IV iron administration may increase the
risk of infection [57].
Studies comparing iron sucrose with oral
iron administration consistently show iron
sucrose to be more effective in patients with
CKD, with significantly better outcomes in Hb,
hematocrit, serum ferritin, and TSAT, as well as
reduced recombinant human erythropoietin
(rhEPO) dose requirements [48, 51].
Randomized trials have indicated that iron
sucrose has comparable efficacy to other IV iron
formulations in CKD; for example, ferumoxytol
and iron sucrose have similar efficacy in
patients with CKD, including in patients
undergoing hemodialysis [55, 58]. An addi-
tional trial suggested superior efficacy of iron
1964 Adv Ther (2020) 37:1960–2002
Table 2 Published clinical studies using iron sucrose in chronic kidney disease
Study Inclusion criteria Patients, n Patient dialysis status Iron dose (mg)/dose,
interval, treatment
duration
Outcomes and safety information




















Significantly fewer events (non-fatal MI, non-fatal
stroke, hospitalization for heart failure, or death)
with high-dose IS versus low-dose IS (29.3% vs.
32.3%; p\ 0.001 [non-inferiority]; p = 0.04
[superiority])
No differences between groups in SAEs,








IS ? ESA: 15 Hemodialysis 100 mg q.w. Significant hematocrit increase








IS: 60 No dialysis 200 mg, monthly,
1 year
Significant, continuous, and progressive Hb
increase






Hb\ 11.5 g/dL IS: 82 No dialysis 4 9 200 mg, q.w. Hb increase in 74% of patients









Hemodialysis 100 mg, t.i.w. (1000 mg
total)
2 weeks after last injection, decrease in IRLS score
was significantly greater for IS versus placebo, and
increases in SF, TSAT, and Hb were significantly
greater for IS versus placebo




























Study Inclusion criteria Patients, n Patient dialysis status Iron dose (mg)/dose,
interval, treatment
duration





















100 mg q.w. (1000 mg
total; completed in
3 months)
SF levels increased significantly in both groups
Hb levels were similar between groups, but
intermittent IS significantly reduced Hb
variability versus continuous IS








IS ? ESA: 18 Stable peritoneal dialysis 200 mg loading dose,
followed by 100 mg
monthly for
5 months
Hb and SF increased significantly from baseline
ESA dose was reduced in five patients and
discontinued in one
No patients experienced any side effects related to
IS







IS ? ESA: 70
FeS ? ESA:
66
Hemodialysis 100 mg b.i.w. then q.w.
200 mg FeS t.i.d.,
12 weeks
Significant Hb increase versus baseline in both
groups and with IS versus FeS





Hb B 11 g/dL
TSAT B 25%
SF B 300 ng/mL
IS ? ESA: 91
FeS ? ESA:
91
No dialysis 2 9 500 or
5 9 200 mg, 14 days
65 mg t.i.d., 56 days
Significantly better Hb response (DHb C 1.0 g/
dL) and increase with IS versus FeS
Dysgeusia most prominent IS-related GI complaint
(6.6%)
Fewer GI side effects with IS 200 mg (11.5%) and







IS ? ESA: 26
FeS ? ESA:
20
Peritoneal dialysis 200 mg q.w. over
4 weeks then q.2.w.
200 mg FeS t.i.d.,
8 weeks
Significant Hb increase versus baseline in both
groups and with IS versus FeS




























Study Inclusion criteria Patients, n Patient dialysis status Iron dose (mg)/dose,
interval, treatment
duration








IS ± ESA: 69
FeS ± ESA:
67
GFR[ 20 and B 60 mL/
min/1.73 m2 (no
hemodialysis)
IS 200 mg, weeks 0, 2,
4, 6, 8
FeS 325 mg t.i.d.,
8 weeks
24 months
Increases in Hb similar between groups
SF was significantly higher with IS versus FeS only
from baseline to 6 months
IS was associated with greater risk of infections and
cardiovascular complications versus FeS
GI AEs were more common with FeS, whereas gout
was more frequent in the IS group












Hemodialysis IS according to local
package insert/
guidelines
IIso 500 mg, single
bolus
IIso (split dose) 100 mg
(baseline) ? 200 mg
(weeks 2 and 4)
6 weeks (follow-up)
No significant difference in Hb control between
groups
Increases in SF from baseline to weeks 1, 2, and 4
were significantly greater for IIso versus IS











On dialysis and not on
dialysis
200 mg 9 5 within
14 days (non-dialysis)
100 mg for 10
consecutive sessions
(dialysis 2 9 510 mg
within 5 days)
5 weeks (follow-up)
Increases in Hb similar between groups




























Study Inclusion criteria Patients, n Patient dialysis status Iron dose (mg)/dose,
interval, treatment
duration







SF B 800 ng/mL
IS: 97
FeruM: 196
Hemodialysis 100 mg for 10
consecutive sessions
2 9 510 mg within
5 days
5 weeks (follow-up)
Increases in Hb similar between groups






SF B 100 ng/mL










IS 200 mg days 0, 7,
and 14 ? two
additional doses
(max. 1000 mg)
FCM 15 mg/kg days 0
and 7 (max.
1500 mg), day 56
(end of treatment)
Increase in Hb was statistically higher with FCM
versus IS
Increases in SF, TSAT, and serum iron were
significantly greater in the FCM group versus IS
Protocol-defined hypertensive events were
significantly more common with FCM versus IS,
whereas protocol-defined hypotensive events were
more common with IS than FCM
No significant difference in the primary composite
safety endpoint (all-cause death, non-fatal MI,
non-fatal stroke, unstable angina requiring
hospitalization, congestive heart failure requiring
hospitalization or medical intervention, cardiac
arrhythmia, and hypertensive or hypotensive
events) between treatment groups
AE adverse event, b.i.w. twice weekly, ESA erythropoiesis-stimulating agent, ESRD end-stage renal disease, FCM ferric carboxymaltose, FeruM ferumoxytol, FeS
ferrous succinate, GFR glomerular filtration rate, GI gastrointestinal, Hb hemoglobin, IIso iron isomaltoside 1000, iPTH intact parathyroid hormone, IRLS
International Restless Legs Syndrome Study Group rating scale, IS iron sucrose, IV intravenously administered, MI myocardial infarction, q.2.w. every 2 weeks, q.w.



























isomaltose versus iron sucrose in patients with
non-dialysis CKD, although different dosing
regimens make a direct comparison of these
products problematic [59].
Limited data are available on the use of IV
iron in peritoneal dialysis patients. A recent
study has assessed the safety and efficacy of iron
sucrose in this patient population and has
shown that monthly maintenance with iron
sucrose may improve iron parameters and ery-
thropoietin response [54].
Chronic Heart Failure
Iron deficiency and anemia are commonly
observed in patients with CHF. Anemia was
previously thought to be a major contributor to
the progression of CHF [60, 61]. In patients with
CHF, iron deficiency is associated with
increased mortality [24], increased risk of hos-
pitalization [62], and reduced quality of life
[14, 63]. A number of studies have evaluated the
treatment effects of iron sucrose in patients
with anemia and patients without anemia, both
alone [64–68] and in combination with rhEPO
[60, 69, 70]. A summary of the studies on iron
sucrose use in CHF is provided in Table 3.
Intravenous administration of iron sucrose
alone to patients with anemia and CHF
improves the hematological parameters of Hb,
ferritin, and TSAT [64–68]. Reductions in
inflammatory markers such as natriuretic pep-
tides and C-reactive protein (CRP) have also
been observed after iron sucrose treatment
[64, 66, 70].
These biochemical changes appear to be
associated with symptom improvement in
patients with CHF, while in one study,
echocardiographic evaluation demonstrated
significant improvements in left ventricular
systolic diameter and left ventricular diastolic
diameter [66]. In line with these findings, an
improvement in cardiac remodeling was also
observed in another study in patients with CHF
[68].
Inflammatory Bowel Disease and Other
Gastrointestinal Disorders
A summary of the studies of iron sucrose use in
adults with GI disorders is provided in Table 4.
IBD (including Crohn’s disease and ulcera-
tive colitis) is often treated with anti-inflam-
matory drugs, including tumor necrosis factor-
alpha (TNFa) inhibitors. However, the persis-
tence of anemia as a complication despite anti-
TNFa treatment highlights the need for iron
therapy even when biologics are used [71]. Oral
iron therapy, however, is problematic for
patients with IBD as a result of chronic inflam-
mation leading to poor absorption and toler-
ance. In this respect, and consistent with
findings in patients with CKD, several studies in
patients with iron deficiency and iron-defi-
ciency anemia associated with IBD indicate that
iron sucrose is more efficacious than oral iron
therapy [72, 73].
A study in patients with iron-deficiency
anemia and IBD demonstrated significantly
better outcomes in the iron sucrose arm for two
out of three primary endpoints compared with
oral iron sulfate therapy: fewer iron sucrose-
treated patients remained anemic and more
patients achieved Hb reference levels [72].
In a pooled analysis of four trials evaluating a
total of 191 patients with iron-deficiency ane-
mia resulting from GI disorders, greater increa-
ses in Hb levels were apparent in patients
treated with iron sucrose compared with those
receiving oral iron therapy [74]. However, the
interpretation of these findings is somewhat
problematic because patients with Hb levels
below 10 g/dL were given iron sucrose treat-
ment and patients with higher Hb levels (at
least 10 g/dL) were treated with oral ferrous
sulfate therapy. Iron sucrose treatment in
patients with lower Hb levels (below 10 g/dL)
led to 77% of subjects achieving normal Hb
levels after 3 months. Oral administration of
ferrous sulfate in patients with higher baseline
Hb levels (at least 10 g/dL) resulted in 89%
achieving normalized Hb [75]. Although the
authors of this study reported that all patients
were in remission, more details on the overall
disease severity of the two groups would be of
interest. Patients with IBD and severe anemia
(Hb below 10 g/dL) usually have more severe
and relapsing disease associated with a higher
need for iron supplementation compared with
patients with mild anemia and inactive disease.
Moreover, the recurrence of anemia after iron
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Table 3 Published clinical studies using iron sucrose in patients with chronic heart failure
Study Inclusion criteria Patients, n Iron dose (mg)/dose, interval,
treatment duration





Stable systolic heart failure and
Hb B 12 g/dL
IS: 16 200 mg (10 mL) IV bolus over 10 min on
days 1, 3, and 5 of study
IS improved hematological parameters
(Hb, serum iron, SF, TSAT),
symptoms, and exercise capacity
(NYHA functional class, MLHFQ
score, 6MWT). ISC was well tolerated





Octogenarians with anemia and severe,
resistant CHF
IS: 40 Combination of SC EPO (4–5 K IU/
week, increasing to 10 K IU/week to a
target Hb of 12.5 g/dL) and IS 200 mg
in 150 mL saline IV infusion over
60 min every 1–2 weeks until SF
reached 500 lg/L or iron saturation
reached 40% or Hb reached 12.5 g/dL
Mean ± SD duration of follow-up was
17.4 ± 10 months. IS in combination
with EPO significantly increased Hb,
serum iron, SF, and % iron saturation
and also improved NYHA, LVEF, and
VAS index. Significantly fewer
hospitalizations were reported
compared with a comparable period





Individuals with and without diabetes
with moderate to severe resistant CHF
(and CRF); NYHA functional classes







Combination of SC EPO (4–5 K IU/
week, increasing to 10 K IU/week to a
target Hb of 12.5 g/dL) and IS 200 mg
in 150 mL saline IV infusion over
60 min every 1–2 weeks until SF
reached 500 lg/L or iron saturation
reached 40% or Hb reached 12.5 g/dL
In individuals with/without diabetes with
severe CHF and mild to moderate
CRF, correction of anemia by the
combined use of EPO and ISC was
associated with improvements in LVEF
and cardiac functional status (NYHA
and VAS) and slowing of the rate of






Stable advanced CHF (NYHA class
III–IV) and anemia (men,
Hb\ 13.0 g/dL; women,
Hb\ 12.0 g/dL) and mild to moderate
renal dysfunction
IS: 27 EPO (4 K IU/week, adjusted as necessary
to achieve and maintain a target Hb
between 12.5 and 14.5 g/dL). IS
200 mg in 100–200 mL saline IV
infusion over 60–90 min q.w. for
5–6 weeks until SF reached 400 lg/L
or TSAT of 40% or Hb[ 14.5 g/dL.
IS then given every 4–6 weeks to
maintain these levels
Mean ± SD follow-up was
15.3 ± 8.6 months. Long-term
combined therapy with EPO and ISC
increased Hb, reduced NT-proBNP,





























Study Inclusion criteria Patients, n Iron dose (mg)/dose, interval,
treatment duration






LVEF B 35%; NYHA functional class
II–IV; anemia with Hb\ 12.5 g/dL
for men and\ 11.5 g/dL for women;
SF\ 100 ng/mL and/or
TSAT B 20%. Renal insufficiency
(creatinine clearance B 90 mL/min)
IS: 30 200 mg/200 mL ISC 60 min IV infusion
q.w. for 5 weeks
At 6 months post-treatment, patients
receiving ISC infusion experienced
significant increases in Hb level, SF, and
TSAT. Heart rate and body mass index
were significantly reduced in the IS
group, while LVEF was significantly
increased, as were NYHA scores.
Inflammatory markers CRP and NT-
proBNP were also significantly reduced.
Echocardiographic evaluation showed
significant improvements in LVSd and
LVDd, suggesting a positive effect on
cardiac muscle. A significant
improvement in renal function was also
observed. Side effects were minimal
across both groups and no severe drug-





Aged C 21 years with symptomatic CHF
(NYHA functional class II–IV; exercise
limitation pVO2 B 18 mL/kg/min;
Hb\ 12.5 g/dL (group with anemia)
or 12.5–14.5 g/dL (group without
anemia)
IS: 24 IS administered at 200 mg in 50 mL
saline via IV infusion over 30 min q.w.
for 16 weeks. Then at weeks 4, 8, 12,
and 16 thereafter
IS resulted in a significant treatment effect
for SF, TSAT, and Hb levels in the
patients with anemia. An improvement
in exercise tolerance (pVO2), NYHA
functional class, PGA, and fatigue score
was also observed with IS in the patients
with anemia. AE profiles were similar
between groups: 42% and 64% in the IS
and control groups, respectively. All
events were unrelated (76%) or unlikely




























Study Inclusion criteria Patients, n Iron dose (mg)/dose, interval,
treatment duration






Aged C 18 years; NYHA functional class
II–IV and able to perform
ergospirometry; LVEF\ 40%; Hb C 9





IS 200 mg IV infusion over 30 min q.w.
for 5 weeks then oral placebo t.i.d. for
8 weeks
FeS 200 mg orally t.i.d. for 8 weeks then
IV placebo q.w. for 5 weeks
Oral placebo t.i.d. for 8 weeks, then IV
placebo q.w. for 5 weeks
3-month follow-up
Correction of anemia, defined as
Hb[ 12 g/dL for women and[ 13 g/
dL for men, was achieved by two
patients with IS, three with FeS, and
two with placebo. Hb increase[ 1.5 g/
dL occurred in three patients each in
the IS and FeS groups. SF levels
increased from baseline with both IS
and FeS (but not placebo), but this was
only statistically significant for FeS.
TSAT[ 20% was achieved by five
patients in each of the IS and FeS
groups
pVO2 increased by 3.5 mL/kg/min with
IS whereas there was no change in pVO2






Hb\ 11 g/dL on two occasions within
1 week; serum creatinine\ 4 mg/dL
and NYHA classification III/IV




IS 100 mg IV q3w for 3 weeks, then q.w.
for 23 weeks (total dose 3200 mg of
elemental iron over 26 weeks)
Hb, serum iron, SF, and TSAT were
significantly lower in patients with
NYHA classification III/IV versus
healthy controls at baseline. The mean
values of these parameters were
significantly increased after 6 months of
treatment with IV IS versus baseline.
There were no AEs noted in any patient
6MWT 6-min walk test, AE adverse event, CHF chronic heart failure, CRF chronic renal failure, CRP C-reactive protein, EPO erythropoietin, FeS ferrous sulfate,
Hb hemoglobin, IS iron sucrose, ISC iron sucrose complex, IV intravenous, LVDd left ventricular diastolic diameter, LVEF left ventricular ejection fraction, LVSd
left ventricular systolic diameter, MLHFQ Minnesota Living with Heart Failure Questionnaire, NT-proBNP N-terminal pro-B-type natriuretic peptide, NYHA
New York Heart Association, PGA Patient Global Assessment, pVO2 peak oxygen uptake, q3w every 3 weeks, q.w. weekly, SC subcutaneous, SD standard deviation,



























Table 4 Published clinical studies using iron sucrose in gastrointestinal disorders





Outcomes and safety information







200 mg q.w. or q.2.w. up to
cumulative dose of
1000 mg
100 mg b.i.d., 20 weeks
66% versus 47% Hb response to IS versus FeS (p = 0.07)
One possibly related SAE (thrombocytopenia) with IS, AEs with FeS
dominated by GI events
Lee et al. (2017)
[73]
TSAT\ 16% ± SF\ 30 ng/mL (if




3 9 300 mg (iron deficiency




Hb and TSAT levels similar between groups
SF significantly higher with IS versus FeS
Gut microbiota and metabolome altered differently by FeS and IS
Gisbert et al.
(2009) [75]





200 mg b.i.w. if Hb\ 10 g/
dL until calculated dose
106 mg q.d. if Hb[ 10 g/
dL
77% and 89% response rate in IS and FeS group, respectively
No AEs with IS, 5.1% with oral iron therapy intolerance (nausea,
abdominal pain, and constipation), which led to discontinuation of
treatment






Hb B 12 g/dL (one study); B 11 g/dL
(three studies)
SF B 100 ng/mL or B 300 ng/mL if








15 mg/kg or 750 mg
(variable dosing schedules)
Hb, SF, and TSAT values increased significantly from baseline for all
groups, with the exception of SF values in the oral iron group
FCM and IS resulted in greater increases in Hb than orally administered
and other IV iron products, which may be due to lower baseline Hb levels
Safety profile of FCM was comparable with the other agents










200 mg (up to 11 doses)
Maximum of three infusions
of 1000 or 500 mg
More patients with FCM than IS achieved Hb response (p = 0.04) or Hb
normalization (p = 0.015). Both treatments improved quality of life
scores by week 12
Study drugs were well tolerated and drug-related AEs were in line with
drug-specific clinical experience
AE adverse event, b.i.d. twice daily, b.i.w. twice weekly, CRP C-reactive protein, FCM ferric carboxymaltose, FeS ferrous sulfate, GI gastrointestinal, Hb hemoglobin, IS iron sucrose, IV
intravenous, q.2.w. every 2 weeks, q.d. daily, q.w. weekly, SAE serious adverse event, SF serum ferritin, TSAT transferrin saturation



























treatment may be higher in patients with severe
anemia.
When comparing iron sucrose with ferric
carboxymaltose (FCM), Hb response rates were
similar to those seen in the studies described
above and in Table 4; however, outcomes with
FCM were significantly better [76]. The pooled
analysis in patients with GI disorders described
above found that FCM was associated with
greater increases in ferritin and TSAT compared
with iron sucrose, although increases in Hb
levels were similar [74].
Pediatric studies in children with GI disorders
are summarized in the relevant section below.
Women’s Health, Including Obstetrics
and Gynecology
A summary of the studies investigating iron
sucrose use in women’s health (including in the
pregnancy and postpartum settings) is provided
in Table 5.
Pregnancy and Postpartum
Maintenance of normal iron stores is important
not only for the health of the prospectivemother,
but also for that of her child. A recent summary of
meta-analyses of the effects of iron status and iron
therapy concluded that maternal anemia was
associated with adverse birth and neonatal out-
comes and that iron treatment reduced the risk of
this [77]. A recent Swedish cohort study of
over 500,000 children born between 1987 and
2010 and followedupuntil the end of 2016 found
that the risks of developing autism, attention-
deficit hyperactivity disorder, and intellectual
disabilitywereall increased inchildrenofmothers
who had prenatal anemia during the first
30 weeks of pregnancy [78].
Reflecting results in CKD and IBD, studies in
pregnant women with iron deficiency indicate
that iron sucrose is more effective than oral iron
administration and is at least as effective in
pregnant women with iron-deficiency anemia.
For women with severe iron deficiency during
pregnancy, iron sucrose treatment has been
shown to increase Hb levels more effectively
than an oral iron polymaltose complex [79],
whereas in pregnant women with less severe
iron-deficiency anemia and in those using iron
prophylactically, Hb levels were comparable
following either iron sucrose or oral ferrous
sulfate treatment [80, 81].
Administering iron sucrose from the third
trimester to pre-delivery can significantly
increase Hb levels and reduce blood transfusion
rates in pregnant women with third trimester
Hb levels below 9.5 g/dL, compared with
patients who did not receive iron sucrose [83].
Treatment with a minimum of three iron
sucrose doses at least 2 weeks prior to delivery
appears optimal for increasing Hb levels and
treating antepartum anemia [84].
Addition of rhEPO to iron sucrose therapy
can enhance the effectiveness of treatment of
iron-deficiency anemia in pregnancy. In a study
of pregnant women with iron-deficiency ane-
mia resistant to treatment with oral iron ther-
apy alone, iron sucrose administered either with
or without rhEPO effectively treated anemia.
However, increases in reticulocytes and hemat-
ocrit were greater, and more patients achieved
target Hb levels at 4 weeks with the combina-
tion of rhEPO and iron sucrose compared with
iron sucrose alone. Safety was similar in the two
treatment groups [85]. Selective addition of
rhEPO to iron sucrose for women with severe
anemia or an inadequate response to iron
sucrose alone has also been shown to be an
effective approach to treatment of iron-defi-
ciency anemia in pregnancy [86].
Furthermore, iron sucrose has demonstrated
equal if not superior efficacy compared with
oral iron administration in women with iron-
deficiency anemia in the postpartum setting.
For these women, a study has shown that iron
sucrose treatment can achieve higher Hb levels
than oral ferrous sulfate treatment [88]. Iron
sucrose followed by standard oral iron treat-
ment after 4 weeks also replenished iron stores
more rapidly and resulted in a greater
improvement in fatigue score compared with
oral iron treatment alone in a randomized study
of women with postpartum iron-deficiency
anemia [90].
The effectiveness of iron sucrose either with
or without rhEPO was assessed in a randomized
study in women with severe postpartum ane-
mia. Hb returned to near-normal levels within
1974 Adv Ther (2020) 37:1960–2002
Table 5 Published clinical studies using iron sucrose in obstetrics, gynecology, and women’s health disorders
Study Inclusion
criteria
Patients, n Iron dose (mg)/dose, interval,
treatment duration
Outcomes and safety information










IS: 200 mg q.d. or t.i.w.
FeS: 60 mg t.i.d.
Significantly higher Hb levels with IS versus FeS
Self-limiting fever and tightness in skin (one each) with IS, 30% GI











IS: 200 mg until calculated dose,
5 days
IPC: 100 mg t.i.d., whole
pregnancy
Significantly better Hb increase with IS versus IPC
Possibly related AEs to IS: metallic taste (n = 11), hot flush (n = 12),
dizziness (n = 8), nausea (n = 5), arthralgia (n = 1), vomiting
(n = 1); significantly fewer GI symptoms with IS versus FeS (13.3%









IS: 6 9 200 mg until calculated
dose, 21 days
FeS: 80 mg t.i.d., 4 weeks
Hb increase in both groups without significant difference
‘‘Not-unpleasant taste’’ only AE with IS, during injection (dysgeusia).










IS: 200 or 300 mg
FeS: 80 mg q.d.
Significant Hb increase versus baseline in both groups
Mild anemia (16.2%), infections (6.9%), muscle pains (2.3%), pruritus
(2.3%), cough (1.5%), breast disorders (1.5%) with IS; GI events
only with FeS (17.7%), 14 SAEs in IS group (preterm contractions
n = 3, premature rupture of the membranes n = 3, moderate
anemia after delivery n = 2, threatened preterm delivery because of
cervical insufficiency n = 2, intrauterine growth restriction n = 2,
infection n = 1, injury n = 1), seven SAEs in FeS group (preterm
contractions n = 2, vaginal bleeding n = 1, premature rupture of
the membrane n = 1, infection n = 1, gestational diabetes mellitus






























Patients, n Iron dose (mg)/dose, interval,
treatment duration










C 1 antepartum 300 mg IS dose IS and iron dextran were equally effective in treatment of IDA during
pregnancy







C 1 antepartum 300 mg IS dose The earlier IS was received before delivery, the greater the median Hb
increase. Only those receiving IS[ 2 weeks before delivery had a
significant increase in Hb level from third trimester to delivery.
Increasing administrations incrementally impacted Hb difference
from third trimester to delivery, with only those receiving C 3
doses demonstrating statistically significant Hb change compared







Exact doses not stated Third trimester Hb was lower in the IS group compared with the no
IS group
Despite lower starting Hb in the IS group, antepartum IS reduced





SF B 15 ng/mL
IS: 20
IS ? ESA: 20
200 mg, b.i.w. Both regimens were effective; increases in hematocrit were greater
from day 11 (p\ 0.01) and the median duration of therapy was
shorter (18 vs. 25 days) with adjuvant ESA





SF B 15 ng/mL
IS: 27
IS ? ESA: 57
200 mg, b.i.w. IS or IS ? ESA was effective: the overall Hb level after therapy was
11.0 g/dL (note: 32 patients responded poorly initially to IS alone,
thus receiving additional ESA)






























Patients, n Iron dose (mg)/dose, interval,
treatment duration




SF B 15 ng/mL IS ? ESA: 19 100 mg, b.i.w. At the end of therapy, Hb, HCT, and serum EPO were statistically
significantly improved cf. at the start (p = 0.01, p = 0.004, and
p = 0.006, respectively)







IS: 200 mg e.o.d., 3 days
FeS: 200 mg b.i.d., 6 weeks
Significantly better Hb increase with IS versus FeS
23% metallic taste, 18% facial flushing with IS, 33% GI events with
FeS








IS: 100 mg q.d., 3 days
FeProtSu: 800 mg q.d., 28 days
Significantly better Hb increase with IS versus FeProtSu
Two AEs with IS (headache, nausea), 11 AEs with FeProtSu
(constipation n = 5, hiccup n = 4, heartburn n = 2)
Westad et al.
(2008) [90]
Hb 6.5–8.5 g/dL IS: 58
FeS: 70
IS: 200 mg q.d., 3 days
FeS: 100 mg b.i.d., 12 weeks
Hb increase in both groups
Few and transient AEs with IS (phlebitis, pain at injection site),





Hb 6–8 g/dL IS ? FeS: 36
Placebo ? FeS:
36
IS: 200 mg q.d., 2 days
FeS: 525 mg b.i.d., 30 days
Hb values were comparable in women receiving IS or placebo in
addition to oral iron therapy at any of the time points. No
differences were found between clinical symptoms of anemia,








IS ? ESA: 20
200 mg q.d., 4 days Hb values were close to normal in both groups within 2 weeks
Both treatments were well tolerated; minor side effects included






























Patients, n Iron dose (mg)/dose, interval,
treatment duration








IS ? rhEPO 1:
19
IS ? rhEPO 2:
15
IS: 200 mg q.d., day 0, day 3
IS ? rhEPO 1: IS 200 mg q.d., day
0, day 3 ? rhEPO 10,000 U on
day 0, day 3
IS ? rhEPO 2: IS 200 mg q.d., day
0, day 3 ? rhEPO 20,000 U on
day 0, day 3
Hb increased significantly in all three groups over time (p\ 0.001),
and there were no differences between the treatment groups on any
day of evaluation (p = 0.59). The total mean increment in Hb in




Hb\ 10.0 g/dL IS: 20
IS ? ESA: 20
Oral iron: 20
200 mg q.d., 4 days All three regimens were effective; day 7 hematocrit increases were
higher with adjuvant ESA than for IS or oral iron alone: 8% versus
5% and 4%, respectively (both comparisons p\ 0.01)
Well tolerated




Hb C 12.0 g/dL
SF B 50 ng/mL
IS: 43
Placebo: 47
200 mg q.d., 4 days Trend for better improvement of fatigue score with IS versus placebo
21% drug-related AEs with IS (nausea, chills, headache, dizziness,









IS: 200 mg q.d. (B 600 mg/week)
FCM:\ 50 kg, 500 mg/
week; C 50 kg, 1000 mg/week
FCM was as effective as IS in achieving Hb C 10 g/dL within
2 weeks after first administration (78.8% vs. 72.3%). The time to
reach Hb C 10 g/dL was significantly shorter in the FCM group
versus the IS group (7.7 days vs. 10.5 days). Mean Hb levels were
higher in the FCM-treated patients than in the IS-treated patients
(borderline significance, p = 0.013). QoL scores did not differ
between groups. No deaths, anaphylactic reactions, or transfusion
requirements were reported in either group. All AEs were mild
AE adverse event, b.i.d. twice daily, b.i.w. twice weekly, e.o.d. every other day; EPO erythropoietin, ESA erythropoiesis-stimulating agent, FCM ferrous carboxy-
maltose, FeProtSu ferrous protein succinylate, FeS ferrous sulfate, Gest. gestational, GI gastrointestinal, HCT hematocrit, Hb hemoglobin, IDA iron-deficiency
anemia, IPC iron polymaltose complex, IS iron sucrose, q.d. daily, QoL quality of life, SAE serious adverse event, rhEPO recombinant human erythropoietin, SF



























2 weeks in both treatment groups. The findings
suggest that iron sucrose alone is sufficient for
the treatment of postpartum anemia for most
women, although additional rhEPO treatment
may benefit a subgroup of patients with pro-
nounced inflammatory responses [91]. A second
study in women with postpartum anemia found
that the addition of rhEPO did not further
increase Hb concentrations above those
achieved with IV iron sucrose treatment alone
[92], while another study reported greatest
hematocrit increases with rhEPO and iron
sucrose compared with either iron sucrose or
oral iron treatment alone (both p\0.01) [93].
General Women’s Health
Besides its use in pregnant women with iron-
deficiency anemia, iron treatment can also
benefit women with low ferritin levels and
without anemia. In fatigued, premenopausal
women with low ferritin levels and without
anemia, iron sucrose treatment (four infusions
of 200 mg iron during the first two study weeks)
showed a trend toward a greater improvement
in fatigue compared with placebo. The differ-
ence between the groups was significant in
those with initial serum ferritin levels of 15 ng/
mL or below [94].
A large number of women are iron deficient
and suffer from fatigue. It has therefore been
suggested that parenteral iron administration
could benefit many women and could become
more accepted. However, those who will benefit
most, and the doses of iron required for an
effect, need to be further defined [95].
Two randomized clinical studies have
demonstrated that iron sucrose is effective for
the correction of iron-deficiency anemia due to
heavy menstrual bleeding (menorrhagia)
[96, 97]; in one study, 72% of women who
received treatment with iron sucrose achieved
Hb levels of at least 10 g/dL within 2 weeks after
the first administration [96].
Patient Blood Management
A summary of the studies assessing iron sucrose
use in patient blood management is provided in
Table 6.
Preoperative Iron Treatment
Preoperative anemia is present in 30–40% of
patients scheduled for elective surgery and can
complicate surgery, increasing the likelihood of
blood transfusion or intensive care admission,
increasing the risk of infections or throm-
boembolic events, and prolonging the length of
hospital stay [35, 98–100]. In addition, and as
mentioned previously, in patients undergoing
elective cardiac surgery, iron deficiency with
and without concomitant anemia is associated
with a threefold increase in mortality, more
postoperative serious adverse outcomes, more
blood transfusions, and longer intensive care
and hospital stay than patients without iron
deficiency [25].
Iron sucrose is an effective pre-surgical
treatment for iron-deficiency anemia and has
been shown to increase Hb, ferritin, and soluble
transferrin receptor levels when administered
prior to orthopedic surgery [101]. Increases in
Hb were greatest 2 weeks after initiating iron
sucrose treatment, suggesting that the optimal
time to initiate iron sucrose may be 2–3 weeks
prior to elective surgery [101].
In patients without anemia receiving
rhEPO who were due for elective surgery, iron
sucrose was associated with significantly
higher ferritin and reticulocyte counts than
with oral ferrous sulfate therapy, and pre-
vented iatrogenic iron depletion [102]. In a
separate study, there was no difference
between oral iron therapy and IV iron in
supporting preoperative erythropoietin-driven
stimulation of erythropoiesis (transfusions
were not reported) [103].
A benefit of iron sucrose and an ESA was also
demonstrated in patients undergoing surgery
for hip fractures. Combined treatment resulted
in increased Hb levels and a lower transfusion
rate compared with the use of either iron
sucrose or ESA alone [104].
In surgical patients with iron-deficiency
anemia resulting from heavy menstrual bleed-
ing, iron sucrose achieved significantly better
preoperative Hb and ferritin levels than oral
iron protein succinylate treatment [105]. How-
ever, the study is limited by the premature ces-
sation of the oral iron arm in the study.
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Table 6 Published clinical studies using iron sucrose in patient blood management
Study Inclusion criteria Patients, n Iron dose (mg)/dose,
interval, treatment
duration
Outcomes and safety information







IS: 20 900 mg over 10 days Hb and SF levels increased significantly. TSAT did not
change significantly. Endogenous EPO decreased from
261 to 190 pg/mL 2 weeks after IV iron treatment
(p = 0.050, not significant after Bonferroni correction)







IS ? ESA: 6
FeS ? ESA: 6
IS: 200 mg b.i.w., 3 weeks
FeS: 160 mg/day, 3 weeks
Hb levels increased in both groups; Hb level increased
significantly over 3 weeks with IS ? ESA but not with
FeS ? ESA
Preoperative reticulocyte count and SF were significantly
higher with IS ? ESA than FeS ? ESA
No dose-limiting AEs or allergic reactions were observed








Hb C 10.0 to
B 13.0 g/dL
SF C 50 ng/mL
IS ? ESA: 29
Oral iron ? ESA: 29
IS ? placebo: 25
Oral iron ? placebo: 27
IS: 200 mg day 1 and day 8
Oral iron: 200 mg/day,
2 weeks
IS ? ESA and oral iron ? ESA significantly increased total
RBC production, Hb, HCT, and reticulocytes versus
respective placebo groups; no significant differences for
IS ? ESA versus oral iron ? ESA
IS ? placebo, and oral iron ? placebo was not associated
with increases in hematological values
Incidence of AEs similar between groups; no thrombotic




























Study Inclusion criteria Patients, n Iron dose (mg)/dose,
interval, treatment
duration









IS ? ESA: 11
No iron: 11 (neither
anemic nor iron deficient)
IS: 200 mg q.d., 12 days
IS ? ESA: 200 mg q.d., days
1, 4, 8, 12
In the IS group, no patients could donate autologous blood
compared with all patients in the IS ? ESA group
36% of patients in the IS group received perioperative
transfusion of homologous blood compared with none in
the IS ? ESA group








IS ? ESA: 32
3 days before surgery
Dose not stated
Combined IS ? ESA was more effective than either EPO
or IS alone
Hb increased significantly more after IS ? ESA than after
either EPO or IS alone
No significant difference in the incidence of adverse drug








200 mg, e.o.d. t.i.w.
80 mg q.d., 3 weeks
Significantly better Hb increase and response rate with IS
versus FeProtSu
Two myalgia events and one injection pain event with IS;
one event each of nausea and dyspepsia with FeProtSu; no
severe AEs reported








IS ? ESA: 12
No iron: 13
200 mg days 1, 2, 3
postoperatively
With no between-group differences, early postoperative
treatment with IS alone or in combination with ESA did





























Study Inclusion criteria Patients, n Iron dose (mg)/dose,
interval, treatment
duration









IS ? ESA: 40
No iron: 40
200 mg q.d. to reach total
iron deficit
No significant difference in transfusion rates
No significant difference in Hb increase
Postoperative IS, with or without ESA, is not effective at
correcting postoperative anemia










200 mg, 3 9 e.o.d. No significant difference in RBC transfusions between
groups
3.0% AE-related treatment suspension with IS (one skin
rash, two general discomfort); overall, 14.8% infections














IS: 100 mg 9 3 during
perioperative period
Oral iron: 105 mg q.d. pre-
and postoperatively, and
1 month after discharge
No between-group differences in Hb, HCT, or transfusions
Neither IS nor oral iron therapy were effective in correcting
anemia after cardiac surgery







1869 patients from 12
clinical trials
Various IV iron Perioperative IV iron during orthopedic surgery, especially
postoperatively, appears to reduce the proportion of
patients transfused and units transfused, with shorter








or\ 13.0 g/dL (men)




200 mg e.o.d., until total
iron deficiency was
achieved
Hb concentration and proportion of patients with anemia
corrected or achieving Hb increments[ 2.0 g/dL were
significantly greater for IS than placebo 14 days
postoperatively, but not 7 days postoperatively
SF were significantly higher for IS versus placebo 7 days and
14 days postoperatively





























Study Inclusion criteria Patients, n Iron dose (mg)/dose,
interval, treatment
duration






Hb C 10.0 g/dL
IS: 1142
IS ? EPO: 351
FCM: 45
No iron: 1009




Very short-term perioperative IV iron in major lower limb
orthopedic procedures is associated with reduced
allogeneic blood transfusion rates and length of hospital
stay
In patients with hip fracture, IV iron is also associated with
a reduction in postoperative nosocomial infection








IS ? ESA: 40
Transfusion: 12
Transfusion ? IS ? ESA:
51
No treatment: 27
Hb\ 8.5 g/dL: transfusion
Hb 8.5–10 g/dL:
2 9 200 mg (48 h apart)
Hb 10–11 g/dL:
2 9 400 mg (48 h apart)
IS did not reduce the proportion of transfused patients
(56% transfused vs. 44% not transfused receiving IS), but
it did reduce the number of blood units required
Patients who received IS had better functional recovery than
those who did not












IS: 200 mg immediately and
1 day postoperatively
Oral iron: 100 mg b.i.d.
8 days
Superiority of IS was not shown; the minimum clinically
relevant difference in Hb concentrations was not reached
No AEs in the IS group
Constipation (18%), diarrhea (11%), and nausea (4%) were
reported with oral iron
AE adverse event; b.i.d. twice daily, b.i.w. twice weekly, e.o.d. every other day, EPO erythropoietin, ESA erythropoiesis-stimulating agent, FCM ferric carboxymaltose,
FeProtSu ferric protein succinylate, FeS ferrous sulfate, GI gastrointestinal, Hb hemoglobin, HCT hematocrit, IV intravenously administered, IS iron sucrose, q.d.




























Results from four randomized controlled trials
did not find convincing benefits of periopera-
tive iron in orthopedic or cardiac surgery
[106–109]. In contrast, however, a recent meta-
analysis of IV iron therapies, including iron
sucrose, showed that perioperative IV iron
therapy during orthopedic surgery was associ-
ated with several benefits, including reduced
transfusion rates and shorter hospital stays, but
without impacting the mortality rate [110].
Additionally, a separate randomized study
showed that the use of iron sucrose can signif-
icantly increase Hb levels versus placebo control
in patients undergoing cardiac surgery [111].
This is important as patients undergoing cardiac
surgery are at risk of postoperative functional
iron deficiency.
For patients undergoing surgery for fractures,
several studies have suggested a benefit of uti-
lizing iron sucrose, particularly for hip fractures.
A number of improved outcomes have been
associated with perioperative IV iron (including
iron sucrose) in patients undergoing surgery for
hip fracture and arthroplasty, as highlighted in
a pooled analysis of observational data, with
benefits including reduced transfusion rates,
shorter hospital stays, reduced infection rates
(hip fracture only), and lower 30-day mortality
(hip fracture only) [112].
Blood Donors
Birgegård et al. investigated the frequency and
severity of iron depletion in regular blood
donors and the effects of iron sucrose and oral
iron sulfate therapy on iron status [115]. Iron
sucrose was found to substitute iron loss in
blood donors more efficiently compared with
oral iron sulfate treatment, especially in
women, and also reduced the severity of restless
leg syndrome, which can occur as a complica-
tion of iron deficiency.
Oncology
A summary of the studies on iron sucrose use in
oncology is provided in Table 7.
Anemia is a common side effect of cancer
treatments and ESAs may be used to aid in RBC
production. In patients with anemia and lym-
phoproliferative malignancies who were not
receiving chemotherapy, the addition of iron
sucrose to an ESA resulted in a significantly
faster and greater Hb increase compared with
ESA therapy alone [116]. Furthermore, using
data from this study [116], when iron sucrose
was given as an additional therapy, ESA dose
requirements were reduced from week 5
onward, allowing cost savings over the study
period [117].
In patients with multiple myeloma or lym-
phoma who had undergone autologous
hematopoietic cell transplantation, supple-
mentation of an ESA with iron sucrose increased
the proportion of patients with Hb responses
from 79% to 100%, reduced the median
response time, and lowered ESA dose require-
ments compared with those receiving no iron
treatment [118]. There was no impact of iron
sucrose treatment on long-term clinical out-
comes or survival [119].
Utilization of iron sucrose in the absence of
ESAs can also benefit some oncology patients by
improving Hb levels and reducing the need for
RBC transfusions [120–122].
Pediatric Populations
Data on the use of iron sucrose within pediatric
patients are limited. The data that are available,
however, suggest that iron sucrose is an effec-
tive option (Table 8).
In children with, or at risk of, iron defi-
ciency/iron-deficiency anemia, iron sucrose
appears effective in those who cannot tolerate
or do not respond to oral iron therapy (recom-
mended maximum single dose of 7 mg iron per
kg to minimize the risk of AEs) [123]. Where
iron sucrose has been used in children with iron
deficiency and iron-deficiency anemia, signifi-
cant improvements in Hb levels have been
shown [124, 125].
Where children also suffer from IBD, the use
of oral iron therapy is difficult. In this setting,
iron sucrose is effective for the routine man-
agement of iron-deficiency anemia. Children
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Table 7 Published clinical studies using iron sucrose in oncology
Study Inclusion criteria Patients, n Iron dose (mg)/dose,
interval, treatment
duration
Outcomes and safety information









100 mg q.w. (weeks
0–6); 100 mg q.2.w.
(weeks 8–14)
16 weeks (follow-up)
Significantly greater Hb increase from week 8 onward with IS versus
no IS
Proportion of patients with Hb increase C 2 g/dL was significantly
higher with IS (93%) than no IS (53%; p = 0.001)
ESA dose lower with IS than no IS from week 5 onward
AEs were distributed evenly between groups









200 mg on days 28, 42,
and 56 after SCT
Complete Hb response within 18 weeks achieved by 100% with
IS ? ESA, 79% with ESA, 21% with no ESA
Erythropoietic response significantly higher with IS ? ESA than
ESA, resulting in lower ESA use, reduced drug costs, and
improved quality of life scores; effect on transfusions was not
significant
Safety findings were similar between groups
Jaspers et al. (2015)
[119]
[Long-term follow-up











Overall survival (1-year and 5-year) and progression-free survival (1-
year and 5-year) not significantly different between groups
Incidence of infections remained comparable between groups
Other serious complications were uncommon and hardly




Hb\ 10.0 g/dL IS: 22
FeS: 22
IS: 200 mg
FeS: 200 mg t.i.d.
Significantly higher Hb and significantly fewer RBC transfusions
with IS than FeS
Most common AEs were mild nausea and vomiting; no significant
difference in AEs between groups; no SAEs or hypersensitivity
reactions
Kim et al. (2007)
[121]
Hb\ 12.0 g/dL IS: 30
No iron: 45
1 9 200 mg per CT
cycle
Significant reduction in RBC transfusions with IS versus no iron
No treatment-related AEs with IS; transfusion-related allergic
reactions with similar frequency in both groups
AE adverse event, CT chemotherapy, ESA erythropoiesis-stimulating agent, FeS ferrous sulfate, Hb hemoglobin, IS iron sucrose, q.2.w. every 2 weeks, q.w. every



























Table 8 Published clinical studies using iron sucrose in pediatric patients





Outcomes and safety information
Crary et al.
(2011) [123]
Aged B 18 years
C 1 dose of IS
Patients could not have
CKD
IS: 38 Median dose: 100 mg
Median number of
infusions: 3
Patients had a good response to IS, with a median Hb rise of 1.9–3.1 g/dL
depending on the indication
IS was well tolerated with only one serious reaction (temporary and reversible
hypotension) in a patient who had received IS 500 mg, which was greater




Low Hb (adjusted for
age)
IS: 62 Variable depending on
observed Hb and body
weight
All children showed improvements in iron-deficiency anemia between
diagnosis and week 1
IS was well tolerated with mild AEs in 13% of children
Pinsk et al.
(2008) [125]




Did not respond to oral
iron
IS: 45 Variable depending on
observed Hb and body
weight
IS was effective at raising Hb concentration in all patient groups
IS was well tolerated; one patient experienced transient hypotension and






IS: 24 3 mg/kg (maximum
200 mg)
IS was effective for routine management of iron-deficiency anemia in
children with IBD
IS significantly increased mean SF, TSAT, and Hb levels





IS: 39 3 mg/kg (maximum
200 mg)
Mean Hb levels rose to 12.68 mg/dL and 12.86 mg/dL by 3 and 6 months,
respectively, then remained normal ([ 13 mg/dL)
Mean SF/TSAT had normalized by 3 months and remained normal
Significant positive correlations were found between the increase in Hb and









































IS: 16 Variable depending on
observed Hb and body
weight
All patients had increased Hb
Almost 70% of patients achieved therapeutic success (minimum increase of
2 g/dL of Hb and/or normalized Hb levels)







IS: 20 4 9 200 mg over 14 days Clinically significant improvement in fatigue in 19/20 patients at 6 weeks,
3 months, and 6 months after treatment
IS was well tolerated, with IS-related AEs in four (20%) patients: two
reported headache and two reported nausea




























with iron deficiency resulting from IBD (which
was treated with the anti-inflammatory drug
infliximab) displayed significantly increased
mean ferritin, TSAT, and Hb levels after treat-
ment with iron sucrose, and a higher propor-
tion of these children also had normalized
ferritin, TSAT, and Hb levels versus historical
control data from the same patients [126].
Similarly, in a cohort of children with IBD
(mean age 11.3 years) who were mildly to
severely anemic, iron sucrose (median dose
638.4 mg) increased Hb levels in all 16 patients,
and ferritin and TSAT levels were also statisti-
cally higher post-infusion [127]. Another study
in children with IBD showed that correction of
iron-deficiency anemia using IV iron sucrose
therapy was significantly correlated with better
health-related quality of life scores [128].
Whether with anemia or without, post-
menarchal adolescent female inviduals with
iron deficiency tolerate iron sucrose well and
treatment is associated with a sustained increase
in ferritin and improvements in fatigue symp-
toms [129]. Interestingly, Hb levels in female
individuals without anemia remained unchan-
ged, suggesting a non-hematological function
of iron in reducing fatigue.
SAFETY AND TOLERABILITY
OF IRON SUCROSE
Because of the poor absorption and tolerance of
oral iron therapy in patients suffering from
conditions with chronic inflammation, the use
of IV iron treatment has been studied exten-
sively and the safety of iron sucrose use is well
established. Indeed, iron sucrose has been
widely used over many decades, extending to
over 25 million patient-years of clinical use [39].
The safety profile is therefore well established in
many different patient groups, including CKD,
GI disorders, women’s health disorders, oncol-
ogy, cardiology, and for patient blood manage-
ment (Tables 2, 3, 4, 5, 6, 7). To date, more than
50 published clinical studies, covering numer-
ous patient populations, have reported safety
outcomes with administration of iron sucrose;
18 of these studies have been reported in the
last 5 years [40, 46, 47, 50, 52, 53, 58,
66, 73, 74, 111, 113, 114, 126, 127, 129–131].
The summary of product characteristics for
Venofer describes distortion of taste (dysgeusia)
as being the most commonly reported AE at
4.5% [132]; however, this is not considered
serious and in recent studies has only been
reported in 0–2.3% of participants [40, 53, 94].
Other most common AEs with iron sucrose
(occurring in at least 1% and less than 10% of
patients) include hypotension, hypertension,
nausea, and injection site reactions [132]. When
they do occur, these AEs are generally catego-
rized as being mild.
Additional potential AEs of iron sucrose and
other IV iron formulations relate to a positive
iron balance, which can arise if the increase in
total body iron content is not compensated by
equivalent iron losses. Patients receiving long-
term therapy with parenteral iron may remain
in a chronic state of positive iron balance [133].
This may lead to iron overload. Organs that
appear to be most susceptible to the damaging
effects of iron overload are the liver, heart,
endocrine glands, and joints [133]. There is
currently uncertainty around the risks of iron
overload associated with IV iron treatment, but
available data suggest that current treatment
practices, for example in patients with CKD, are
not associated with overt clinical toxicity
despite a theoretical risk of positive iron balance
[134].
Paravenous leakage of medication from the
vein into the surrounding tissue is another
potential complication of intravenously
administered medication. Reactions are usually
minor and transient, characterized by skin irri-
tation, localized pain and inflammation,
although paravenous leakage of IV iron may
also cause long-lasting or permanent skin dis-
coloration [135].
Contradictory evidence exists regarding
whether iron treatment is linked with increased
bacterial infection [136–139]. The REVOKE
study comparing oral iron therapy versus IV
iron sucrose in patients with CKD was termi-
nated early because of significantly more infec-
tion-related AEs occurring in the IV iron group
compared with the oral iron group (28.4% vs.
15.9%) [52]. However, there has been much
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debate surrounding the validity of the safety
analyses from this study [140]. Questions have
been raised regarding the statistical analyses
driving the significance of the study findings;
results were only significant when the analyses
were adjusted for prognostic baseline charac-
teristics (e.g., age, cardiovascular disease, and
hospitalized infections) [141]. Several research-
ers have queried whether such adjustments
were appropriate within a randomized trial
[141, 142]. Also, in a systematic review and
meta-analysis of IV versus oral iron supple-
mentation for the treatment of anemia in CKD,
REVOKE was identified as the only study at high
risk of bias for selective outcome reporting
according to the Cochrane criteria [143]. In
contrast, the randomized FIND-CKD study
found similar infection rates (most commonly
of the urinary tract) between IV FCM (targeting
higher [400–600 lg/L] or lower [100–200 lg/L]
ferritin) and oral iron therapy [36, 140]. There
was also a comparable rate of hospitalization
because of infection between the FCM groups
and oral iron therapy [140]. Most data associ-
ating IV iron with increased infection risk are
derived from observational studies, and the
evidence examining an association between IV
iron use and infection is inconclusive. During a
Kidney Disease: Improving Global Outcomes
(KDIGO) Controversies Conference, it was
concluded that there was insufficient evidence
on the potential dangers of long-term IV iron
treatment [133]. At the time, the authors of that
report welcomed the upcoming PIVOTAL study
as a randomized trial that would provide con-
crete answers to these safety questions [40]. The
PIVOTAL study has since been published and is
the largest randomized trial that has been per-
formed with any IV iron. This multicenter study
reported the same overall infection rates, as well
as hospitalization and death from infection,
between a proactive high-dose iron sucrose
strategy and a reactive low-dose iron sucrose
strategy in incident patients undergoing main-
tenance hemodialysis [40]. Moreover, a recently
published case-crossover study specifically
assessed whether IV iron treatment increases
the risk of infectious disease. They found that IV
iron treatment did not increase short-term
infection risk among hemodialysis patients
[144]. Nevertheless, consistent with previous
recommendations in patients with CKD [33],
avoidance of IV iron should be considered in
the setting of active systemic infection to pre-
vent hypothetically exacerbating the infection.
As noted previously, various IV iron formu-
lations exist. Bailie et al. compared AE profiles
for iron sucrose, iron dextrans, and ferric glu-
conate using US Food and Drug Administration
(FDA) and World Health Organization (WHO)
pharmacovigilance databases between 1997 and
2009 [145, 146]. Data revealed that iron sucrose
use was associated with a significantly lower
rate of AEs compared with iron dextran (highest
rate) and ferric gluconate (intermediate rate).
While a retrospective cohort of patients with
hemodialysis-dependent CKD displayed similar
longer-term safety profiles when receiving iron
sucrose or ferric gluconate, modest decreases in
infection-related hospitalizations and deaths
were observed in those receiving iron sucrose
[131]. Moreover, iron sucrose was associated
with fewer type 1 hypersensitivity AEs and a
lower incidence of life-threatening allergic AEs
compared with iron dextran and ferric glu-
conate [145, 146], and was rarely associated
with non-anaphylactoid reactions (e.g., non-
life-threatening hypotension, nausea, and
exanthema) [147]. Iron sucrose can also be
administered to patients with intolerance to
iron dextran or ferric gluconate [147]. Hyper-
sensitivity reactions with IV iron therapy are
generally very rare, but findings have varied
among different IV iron treatments. In a recent
retrospective pharmacoepidemiological study
comparing all available IV iron products, iron
sucrose showed one of the lowest reporting
rates for severe hypersensitivity, although the
limitations of such analyses of pharmacovigi-
lance data are well recognized [148]. Similarly,
among patients in a study in the US Medicare
non-dialysis population to compare the risk of
anaphylaxis among marketed IV iron products,
anaphylaxis risk was lowest for iron sucrose
[149].
A number of studies in pregnant women
have shown there to be no serious AEs when
using iron sucrose (Table 5) [79–82, 150].
Although side effects were reported in 40/130
(30.8%) patients in a study comparing iron
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sucrose versus oral iron therapy, no serious AEs
were associated with iron sucrose [51]. Iron
sucrose is also well tolerated in pediatric
patients (Table 8) [123, 126]. For example, in a
study of 38 children receiving iron sucrose, only
one serious AE (anaphylaxis) was reported, and
that occurred in a patient who had received
more than the recommended dose [86].
On the basis of safety data obtained over
many years and the wealth of published infor-
mation on iron sucrose, it is clear that IV iron
treatment is highly beneficial to a wide range of
patients. The European Medicines Agency
(EMA) assessed the use of IV iron-containing
medicinal products and concluded that the
benefits of these medicines outweigh the risks
where oral iron therapy is poorly tolerated or
insufficient [151].
EXPERIENCE WITH OTHER IRON
SUCROSE SIMILARS/REGULATORY
UPDATE
The European Union categorizes follow-on
products as generics (synthetic molecules) or
biosimilars (from organic sources) that demon-
strate equal therapeutic equivalence despite
having a different mode of action than their
reference product [152, 153]. During the last
few decades, several follow-on iron sucrose
products (iron sucrose similars) were approved
as generics in the European market [154]. A
growing body of clinical [155–159] and non-
clinical [156, 160] evidence has nevertheless
challenged the perception that originator iron
sucrose and iron sucrose similars are inter-
changeable [152, 161].
Venofer contains a colloidal solution of
nanoparticles consisting of a polynuclear Fe(III)
oxyhydroxide/oxide core stabilized by an iron
sucrose shell. Unlike most pharmaceuticals,
Venofer is not a small molecule but a non-bio-
logical complex drug (NBCD) and is part of the
class of drugs called nanomedicines [162]. The
stabilized iron(III) hydroxide–sucrose complex
in Venofer is produced through a unique man-
ufacturing process. Nanomedicines, being
NBCDs, consist of a multitude of closely related
structures for which the entire complex is the
active pharmaceutical ingredient [163]. Their
properties cannot be fully characterized by
physicochemical analysis, and a well-con-
trolled, robust manufacturing process is funda-
mental to reproducing the product; these
properties make general similars particularly
difficult to generate [164].
These complex nanomedicines have brought
about a class of similars termed nanosimilars
[164]. Given the complex nature of
nanomedicines, regulations governing generics
may be inadequate for nanosimilars. Nanosim-
ilars present unique challenges in determining
equivalence to originator products as a result of
difficulties establishing the equivalence of
active ingredients, physiochemical properties,
and in vivo drug exposure [165]. As a conse-
quence, without head-to-head clinical studies
demonstrating therapeutic equivalence, substi-
tution of nanomedicines, such as iron sucrose,
is not recommended [161] as safety concerns
outweigh potential cost benefits [155].
The current regulatory paradigm consists of
initially demonstrating qualitative and quanti-
tative formulation equivalence with the refer-
ence drug, followed by physiochemical
equivalence (e.g., particle size/distribution) and
finally equivalent systemic exposure [165, 166].
This becomes more challenging with increasing
complexity of the molecule or agent (Fig. 1).
Although both the US FDA and EMA use
close/comparable approaches to approving
generic small-molecule drugs, they differ in
their approaches to approving nanosimilars and
there are no consensus requirements [165]. The
inadequacy of a ‘‘one size fits all’’ approach to
approving nanosimilars is reflected in the
observed clinical differences in original formu-
lations versus similars when they have been
approved via a generic approach [164]. Specific
areas of concern include the stability of the
colloidal suspension and direct interaction of
nanoparticles with the innate immune system.
In a group of 658 gynecological operative
and postpartum women, there were numeri-
cally more AEs (p\0.2) in patients receiving an
iron sucrose similar compared with those
receiving iron sucrose [155]. A sequential
observational study assessed the impact of
switching from iron sucrose to an iron sucrose
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similar, by comparing two periods of 27 weeks
each in 75 stable hemodialysis patients also
receiving an IV ESA. Patients received iron
sucrose in the first period and an iron sucrose
similar in the second. Mean Hb and mean TSAT
values were decreased during the second period.
The mean IV iron dose, as well as the mean ESA
dose per patient per week, was lower in the first
period, and the total mean anemia drug costs
increased by 12% in the second period. This
study showed that switching from original iron
sucrose to an iron sucrose similar in a group of
patients with CKD undergoing hemodialysis led
to destabilization of a well-controlled popula-
tion and counterintuitively resulted in
increased total drug costs [157]. In cases
where patients with hemodialysis-dependent
CKD had their iron sucrose similar replaced
with the original iron sucrose, the requirements
for IV iron dropped by a third, ESA doses were
reduced, and TSAT and ferritin levels rose
[155, 157, 159]. Interchanging or substituting
an original nanomedicine, therefore, is strongly
discouraged until therapeutic and safety equiv-
alence have been demonstrated [161]. This was
further stressed by a recent approval, where the
UK Medicines & Healthcare products Regula-
tory Agency (MHRA) granted marketing autho-
rization to an iron sucrose similar, not as a
generic but as a hybrid medicine, clearly stating
that it is not the same, but only similar to the
reference listed drug [167].
COST-EFFECTIVENESS OF IRON
SUCROSE
Considerable cost savings to healthcare provi-
ders can be made by using IV iron treatment
through its ability to reduce ESA dose
[40, 117, 168–171] as well as reducing the need
for RBC transfusions [40, 113, 118, 121, 172].
Despite iron sucrose similars being designed
to reduce costs [173], these formulations are not
necessarily cost-effective. In a sequential obser-
vational study, switching from iron sucrose to
an iron sucrose similar led to an increase in total
anemia drug costs [157, 173]. Additionally, in a
recent cost-minimization analysis in hemodial-
ysis patients, iron sucrose and iron sucrose
similars were found to have comparable effi-
cacy; however, using an iron sucrose similar was
Fig. 1 Challenges associated with complex drugs in terms
of pharmaceutical equivalence and bioequivalence between
originator products and follow-on similar products.
Figure adapted from Hussaarts et al. [180] (https://
creativecommons.org/licenses/by-nc/4.0/)
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more expensive in 67% of iterations [171].
Although lower costs were associated with iron
sucrose similars, this was offset by the require-
ment for higher ESA doses to obtain equivalent
ferritin and TSAT levels [171].
CONCLUSIONS
Iron therapy through the use of iron sucrose
produces many benefits, as summarized here
and elsewhere [174]. Iron sucrose is able to
correct iron deficiency, in addition to promot-
ing erythropoiesis and subsequently reducing
the required doses of ESAs. Not only is iron
sucrose effective, but it is also well tolerated and
rapidly increases bioavailable iron supplies. This
is important for individuals who are unable to
tolerate oral iron therapy, who are non-com-
pliant with oral treatment, or in whom oral
preparations are not effective. The efficacy and
tolerability of iron sucrose are beneficial across a
broad range of conditions causing or associated
with iron deficiency/iron-deficiency anemia.
Generic substitution of iron sucrose similar for
iron sucrose should not be assumed to provide
therapeutic equivalence, as the complex
physicochemical properties of the original
agent are extremely difficult to duplicate and
studies have not been able to conclusively
demonstrate that iron sucrose similars have
safety and efficacy equivalent to that of iron
sucrose.
EXPERT OPINION
The administration of iron via IV iron sucrose is
beneficial in comparison with oral therapy for
numerous reasons. Iron sucrose has demon-
strated its ability to increase Hb levels with or
without concomitant ESA therapy and
improves both ferritin levels and TSAT.
Administering iron sucrose via the IV route
overcomes low intestinal absorption and
reduced iron release that can hinder the per-
formance of oral treatment. Overall, a hemato-
logical response is achieved more rapidly and
consistently with iron sucrose than with oral
iron administration, which, when considered
along with reductions in ESA doses and the
reduction in additional drugs to manage ane-
mia in patients, can help to ensure that the use
of iron sucrose is cost-effective. In contrast to
earlier days, the EMA does not require a test
dose when administering iron sucrose; how-
ever, there is a requirement for staff to be
trained in cardiopulmonary resuscitation in
case of anaphylaxis.
IV iron use should be considered in patients
with functional iron deficiency and impaired
iron absorption due to chronic inflammatory
conditions, as well as in patients with time-
critical iron deficiency/iron-deficiency anemia.
Iron stores should be replenished before the use
of ESA therapy. IV iron is first-line treatment for
iron-deficiency anemia in patients with CKD
undergoing hemodialysis; it is an option for
patients with non-dialysis CKD, who often have
functional iron deficiency. IV iron is recom-
mended as first-line treatment in patients with
symptomatic heart failure with reduced ejection
fraction and iron deficiency. In patients with
IBD and iron-deficiency anemia, IV iron is
considered as first-line treatment in patients
with clinically active disease, in cases with pre-
vious intolerance to oral iron, and in the pres-
ence of severe anemia (Hb below 10 g/dL). IV
iron and ESAs should be used accordingly in
order to correct pre- and postoperative iron
deficiency anemia. IV iron is an option for
treating iron deficiency/iron-deficiency anemia
during the second or third trimester of preg-
nancy, and in women with iron-deficiency
anemia due to heavy menstrual bleeding.
Patients receiving ongoing chemotherapy who
present with anemia and absolute iron defi-
ciency should be offered IV iron treatment.
Iron sucrose has been studied extensively in
a wide range of patients over many decades and
has favorable tolerability compared with alter-
native IV iron products, such as ferric gluconate
and iron dextran. Indeed, reassuring clinical
data continue to be gained on iron sucrose,
notably from the recently published PIVOTAL
study in CKD comparing the efficacy and safety
of high- versus low-dose iron sucrose.
Moving forward, there is a need for improved
standardization of iron sucrose nanosimilar
regulation that necessitates evidence of
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bioequivalence before substituting with, or
switching to, an iron sucrose similar can be
recommended.
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